Imprimis Pharmaceuticals (NSDQ:IMMY) touted data today from a peer-reviewed study of patients who received its “dropless therapy” following cataract surgery.
The San Diego-based company uses a compounded antibiotic and steroid formulation in single, injectable doses administered by physicians following ocular surgery. The treatment is designed to eliminate the need for patient-administered eye drops, potentially eliminating patient non-compliance or dosing errors. The compounded formulations use Imprimis’ patent-pending SSP technology, which helps active pharmaceutical ingredients solubilize into a well-distributed particle suspension.
Get the full story at our sister site, Drug Delivery Business News.
The post Imprimis touts ‘dropless therapy’ study for cataract surgery appeared first on MassDevice.
from MassDevice http://ift.tt/2dSO4hA
Cap comentari:
Publica un comentari a l'entrada